|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.95 USD | +2.10% |
|
+0.06% | -14.18% |
| 08:31am | Syndax Pharmaceuticals Reports Positive Data From Leukemia Combo Drug Trial | MT |
| 06-10 | Syndax Pharmaceuticals, Inc. - Shareholder/Analyst Call |
| Market Cap | 1.56B 1.35B 1.25B 1.17B 2.18B 149B 2.23B 14.86B 5.76B 71.9B 5.85B 5.72B 250B | P/E Ratio 2026 * |
-10.2x | P/E Ratio 2027 * | -41.6x |
|---|---|---|---|---|---|
| Enterprise Value | 1.79B 1.55B 1.43B 1.34B 2.5B 171B 2.56B 17.06B 6.6B 82.51B 6.71B 6.57B 287B | EV / Sales 2026 * |
5.17x | EV / Sales 2027 * | 3.51x |
| Free-Float |
98.29% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Syndax Pharmaceuticals, Inc.
| 1 day | +2.16% | ||
| 1 week | +0.06% | ||
| Current month | -7.96% | ||
| 1 month | -15.67% | ||
| 3 months | -26.23% | ||
| 6 months | -11.66% | ||
| Current year | -14.18% |
| 1 week | 16.66 |  | 18.13 |
| 1 month | 16.66 | | 21.5 |
| Current year | 16.66 | | 25.59 |
| 1 year | 8.58 | | 25.59 |
| 3 years | 8.58 | | 25.59 |
| 5 years | 8.58 | | 29.86 |
| 10 years | 3.39 | | 29.86 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Metzger
CEO | Chief Executive Officer | 55 | 2022-02-02 |
Peter Ordentlich
CTO | Chief Tech/Sci/R&D Officer | 57 | 2013-10-31 |
Keith Goldan
DFI | Director of Finance/CFO | 54 | 2022-06-12 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Podlesak
CHM | Chairman | 68 | 2008-11-30 |
Michael Metzger
BRD | Director/Board Member | 55 | 2019-07-03 |
Pierre Legault
BRD | Director/Board Member | 65 | 2017-01-03 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-31 | Sell | Chief Executive Officer | -6,847 | 0.0077% | ||
| 05-31 | Sell | Chief Financial Officer | -1,177 | 0.0013% | ||
| 02-08 | Sell | Chief Financial Officer | 3,410 | 0.0039% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.10% | +0.06% | +65.41% | -13.07% | 1.56B | |
| -1.40% | +0.12% | -14.73% | -12.42% | 43.68B | |
| +3.48% | -4.20% | +265.65% | +489.29% | 30.65B | |
| -0.50% | -3.21% | +13.88% | -14.64% | 30.4B | |
| -0.21% | -6.30% | -0.04% | +23.03% | 29.31B | |
| -0.66% | -7.13% | +7.59% | +12.76% | 24.2B | |
| +2.45% | +4.19% | +58.08% | +119.20% | 13.3B | |
| +4.02% | -0.51% | - | - | 13.03B | |
| -1.65% | -1.08% | +7.92% | +8.03% | 13.21B | |
| +1.06% | -1.24% | +105.03% | +78.24% | 12.12B | |
| Average | +1.00% | -1.28% | +56.53% | +76.71% | 21.15B | |
| Weighted average by Cap. | +0.62% | -1.46% | +52.19% | +88.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 346M 300M 276M 259M 484M 33.08B 494M 3.3B 1.28B 15.95B 1.3B 1.27B 55.45B | 510M 442M 408M 382M 714M 48.81B 729M 4.86B 1.88B 23.53B 1.91B 1.87B 81.81B |
| Net income | -152M -132M -122M -114M -213M -14.57B -218M -1.45B -562M -7.02B -571M -559M -24.42B | -36.8M -31.93M -29.44M -27.58M -51.53M -3.52B -52.61M -351M -136M -1.7B -138M -135M -5.91B |
| Net Debt | 230M 199M 184M 172M 322M 22.01B 329M 2.19B 849M 10.61B 863M 844M 36.89B | 232M 202M 186M 174M 326M 22.26B 332M 2.22B 859M 10.73B 873M 854M 37.3B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-11 | 18.04 $ | +2.62% | 597,775 |
| 26-06-10 | 17.58 $ | -0.62% | 1,395,416 |
| 26-06-09 | 17.69 $ | +4.30% | 1,435,471 |
| 26-06-08 | 16.96 $ | -2.19% | 2,338,418 |
| 26-06-05 | 17.34 $ | -3.77% | 2,702,523 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SNDX Stock
Select your edition
All financial news and data tailored to specific country editions
